34

Journal of

*Short Report*

# CLINICAL NEUROMUSCULAR

DISEASE

*Volume 18, Number 1*

*September 2016*

Bilateral Vestibulopathy Aggravates Balance and Gait Disturbances in Sensory Ataxic Neuropathy, Dysarthria, and Ophthalmoparesis: A Case Report

## Roeland B. van Leeuwen, MD, PhD,\* Bart W. Smits, MD, PhD,† Richard J. Rodenburg, PhD,‡ and Baziel G. van Engelen, MD, PhD§

From the \*Department of Neurology, Gelre Hospitals Apeldoorn, Apeldoorn, the Netherlands; †Department of Neurology, Maasstad ziekenhuis, Rotterdam, the Netherlands;

‡NCMD, Radboudumc, Nijmegen, the Netherlands; and

§Department of Neurology, Radboud University Medical Centre, Nijmegen, the Netherlands.

The authors report no conflicts of interest.

Reprints: Roeland B. van Leeuwen, MD, PhD, Department of Neurology, Gelre Hospitals Apeldoorn, P.O. Box 9014, 7300 DS, Apeldoorn, the Netherlands (e-mail: [r.b.van.leeuwen@gelre.nl).](mailto:r.b.van.leeuwen@gelre.nl)

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.

### Abstract

In patients with a triad of sensory ataxic neuropathy, dysarthria, and ophthalmoparesis (SANDO), the presenting features are mainly ataxia or ptosis. SANDO patients often have impaired balance and gait, which is not surpris- ing considering the combination of sensory ataxic neuropathy, and additional symptoms like cerebellar ataxia and limb girdle weakness. We describe a SANDO patient who noticed an increasingly impaired balance and gait, without any dizziness. Neurological investigation re- vealed an external ophthalmeplegia and a cere- bellar ataxia; the head impulse test was not reliable because of eye movement disorders. The caloric reflex tests showed lack of responses on both sides, compatible with severe bilateral vestibulopathy. Making the diagnosis of bilateral vestibulopathy in SANDO patients may have implications for the management of the patient, because specific vestibular rehabilitation can improve gaze and postural stability.

Key Words: SANDO, bilateral vestibulopathy, bal- ance, ataxia

( *J Clin Neuromusc Dis* 2016;18:34–36)

### INTRODUCTION

In 1997, 4 patients were described with a triad of sensory ataxic neuropathy, dysar- thria, and ophthalmoparesis (SANDO), which has long been considered as part of the chronic progressive external ophthalmople- gia (CPEO) spectrum.1 However, a recent study showed that the combination of pro- gressive external ophthalmoparesis and sen- sory ataxic neuropathy (SAN) is associated

with a specific genetic profile. Compared to

CPEO patients without SAN, SANDO patients have a much higher frequency of multiple mitochondrial DNA (mtDNA) deletions.2 Mul- tiple mtDNA deletions are generally caused by mutations in mtDNA maintenance genes, in the case of SANDO mostly in the polymer- ase gamma 1 (*POLG*) and Twinkle helicase (*C10orf2*) genes. Because of this specific genetic profile, SANDO is increasingly being recognized as a distinctive mitochondrial phenotype.

The presenting features in SANDO are

mainly ataxia (67%) or ptosis (24%).2 Mean age at onset is 32 years, though the range is considerable (5–73 years). In addition to the 3 key clinical features making up the acronym, additional symptoms include cer- ebellar ataxia, limb girdle weakness, diabe- tes, seizures, cognitive impairment, and dysphagia.

SANDO patients often have impaired balance and gait, which is not surprising considering the combination of SAN, cerebel- lar ataxia, and limb girdle weakness. In our personal experience however, gait and bal- ance are more profoundly impaired than in patients with similar degrees of neuropathy, ataxia, or muscle weakness.3,4

In this report we describe a SANDO patient with severe bilateral vestibular loss. We hypothesize that in this particular patient, bilateral vestibular loss might have aggravated the already impaired balance and gait.

## Balance and Gait Disturbances in SANDO

Journal of

35

### CASE REPORT

A 54-year-old man first noted ptosis at the age of 34. Over the years he developed several other symptoms including an exter- nal ophthalmoplegia, generalized mild muscle weakness, a length-dependent sen- sory deficit, areflexia, and mild cerebellar ataxia. Hearing and visual acuity remained unaffected.

Several investigations had been per- formed in the years following the first pre- sentation. Electromyogram revealed absence of sensory response in both arms and legs and neurogenic motor units, more pro- foundly in distal than in proximal muscles. Head magnetic resonance imaging showed both cerebellar and cerebral atrophy. Electro- cardiograms were always normal.

At age of 36 a muscle biopsy was taken from the right quadriceps. Muscle histology was unremarkable. Assessment of the mito- chondrial respiratory chain enzymes revealed a moderately decreased complex III activity (68% of the lower normal limit), and a com- plex I activity around the lowest reference value, whereas complex II and citrate syn- thase activities were well above the mean of the reference value.5,6 Genetic investigations revealed multiple mtDNA deletions, which were associated with 2 compound heterozy- gous mutations c.1399 G . A (p.Ala467Thr) and c.2243 G . C (p.Trp748Ser) in the *POLG* gene (NM\_002693). This combination of mu- tations has been described before in SANDO patients.2,7

Two years ago, at the age of 52, the

patient noticed increasingly impaired balance and gait, without any dizziness. During fast movements he experienced a blurred vision. He had never been treated with ototoxic medication, aminoglycosides in particular, nor was he using any other medication.

Neurological examination revealed a ptosis on both sides. Eye movements were restricted in horizontal plane; the head impulse test was not reliable because of eye movement disorders. Diffuse weakness was noted in arms and legs; distal sensation in

arms and legs was reduced, areflexia was present. There was an uncertainty in walking; Romberg was positive. All other coordination tests were intact.

An audiogram was normal for his age. A new head magnetic resonance imaging con- firmed the previous findings of generalized cerebral and cerebellar atrophy, without any abnormalities in the cerebellopontine region. The caloric reflex tests showed lack of responses on both sides, compatible with

severe bilateral vestibulopathy(BV).

Vestibular rehabilitation has been started, with little improvement so far.

### DISCUSSION

BV is defined as a bilateral loss of the labyrinthine function and/or the superior vestibular nerve, and might be caused by ototoxic medication (aminoglycosides in par- ticular), Meniere’s disease, and several neuro- degenerative disorders. To our knowledge, this is the first report of BV in a patient with SANDO, or more specifically, in a patient with a genetic defect in *POLG*.

The clinical presentation of BV can vary significantly. Almost all patients experience decreased gait, especially in the dark or on uneven surfaces. Patients complain about blurred vision during fast head movements (*oscillopsia*), and sometimes about dizziness during fast head movements as well. Finally, patients might experience difficulties with spatial orientation. Dizziness and ear symp- toms are less common. Gait is often impaired and patients are generally unable to perform tandem gait. The head impulse test is abnor- mal in half of the cases. A quarter of BV pa- tients have signs of polyneuropathy and/or cerebellar dysfunction.8

BV is a symptom rather than a disease.

No cause can be found in half of the patients.9,10 The prevalence of BV is low, and thus there is often a long diagnostic delay. The course depends mainly on the underlying disease.

The workup of a suspected BV requires caloric and rotatory chair tests. The former

# CLINICAL NEUROMUSCULAR DISEASE

*Volume 18, Number 1*

*September 2016*

[www.jcnmd.com](http://www.jcnmd.com/)

36

Journal of

*van Leeuwen et al*

# CLINICAL NEUROMUSCULAR

DISEASE

*Volume 18, Number 1*

*September 2016*

reveals vestibular hypofunction or areflexia on both sides, the latter, absence of post- rotatory nystagmus after the chair is suddenly stopped.

As in unilateral vestibular loss, vestibu- lar rehabilitation is the treatment of choice in BV.11,12

Improved gaze and postural stability is reported in 35%–50%.

In our patient the diagnosis of BV was made more than 20 years after disease onset. One possible explanation is that BV did not develop until late in the course of the disease. However, there is also a possibility that BV had gone unnoticed, because impaired bal- ance and gait may very well have been attributed to other symptoms such as SAN, ataxia, and muscle weakness. This raises the question as to whether the association between BV and SANDO in our patient is coincidental, or that BV is yet another symp- tom of the already expanding phenotype of *POLG* mutations.

In favor of a causal relationship is the fact that vestibular dysfunctions have pre- viously been associated with other mitochon- drial disorders, more particular in some of the patients carrying the mtDNA mutation m.3243A./G or the m.1555A./G muta- tion. The m.3243A . G mutation is associ- ated with mitochondrial phenotypes such as mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, maternally inherited diabetes and deafness, CPEO, Leigh syndrome, focal segmental glomerolosclero- sis, and a variety of overlap syndromes. More- over, the m.3243A./G mutations is associated with dysfunction of both the supe- rior and inferior vestibular systems.13 The m.1555A . G mutation is associated with aminoglycoside induced deafness and vestib- ular loss. However, there are also reports of patients carrying the m.1555A . G mutation with saccular and inferior vestibular nerve dysfunction, despite never having been exposed to aminoglycosides.14

In conclusion, this is the first report of

BV in a patient with SANDO caused by *POLG*

mutations. Making the diagnosis of BV in SANDO patients may have implications for the management of the patient, because spe- cific vestibular rehabilitation can improve gaze and postural stability.

REFERENCES

1. Fadic R, Russell JA, Vedanarayanan VV, et al. Sen- sory ataxic neuropathy as the presenting feature of a novel mitochondrial disease. *Neurology*. 1997; 49:239–245.
2. Hanisch F, Kornhuber M, Alston CL, et al. SANDO syndrome in a cohort of 107 patients with CPEO and mitochondrial DNA deletions. *J Neurol Neurosurg Psychiatry.* 2015;86:630–634.
3. McHugh JC, Lonergan R, Howley R, et al. Sensory ataxic neuropathy dysarthria and ophthalmoparesis (SANDO) in a sibling pair with a homozygous p. A467T POLG mutation. *Muscle Nerve.* 2010;41: 265–269.
4. Milone M, Brunetti-Pierri N, Tang LY, et al. Sensory ataxic neuropathy with ophthalmoparesis caused by POLG mutations. *Neuromuscul Disord.* 2008;18: 626–632.
5. Fischer JC, Ruitenbeek W, Trijbels JM, et al. Estimation of NADH oxidation in human skeletal muscle mitochondria. *Clin Chim Acta.* 1986;155: 263–273.
6. Mourmans J, Wendel U, Bentlage HA, et al. Clini- cal heterogeneity in respiratory chain complex III deficiency in childhood. *J Neurol Sci.* 1997;149: 111–117.
7. Tang S, Wang J, Lee NC, et al. Mitochondrial DNA polymerase gamma mutations: an ever expanding molecular and clinical spectrum. *J Med Genet.* 2011;48:669–681.
8. Van de Berg R, van Tilburg M, Kingma H. Bilateral vestibular hypofunction: challenges in establishing the diagnosis. *ORL J Otorhinolaryngol Relat Spec.* 2015;77:197–218.
9. Rinne T, Bronstein AM, Rudge P, et al. Bilateral loss of vestibular function: clinical findings in 53 patients. *J Neurol.* 1998;245:314–321.
10. Zingler CZ, Cnyrim C, Jahn K, et al. Causitive factors and epidemiology of bilateral vestibulopathy in 255 patients. *Ann Neurol.* 2007;61:524–532.
11. Kang CM1 Cabrera, Tusa RJ. Vestibular rehabilita- tion: rationale and indications. *Semin Neurol.* 2013; 33:276–285.
12. Porciuncula F, Johnson CC, Glickman LB. The effect of vestibular rehabilitation on adults with bilateral vestibular hypofunction: a systematic review. *J Vestib Res.* 2012;22:283–298.
13. Iwasaki S, Egami N, Fujimoto C, et al. The mitochon- drial A3243G mutation involves the peripheral vesti- bule as well as the cochlea. *Laryngoscope*. 2011;121: 1821–1824.
14. Kawashima Y, Noguchi Y, Ito T, et al. Vestibular evoked -myogenic potentials in patients with the mitochondrial A1555G mutation. *Laryngoscope*. 2009;119:1874.

*Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.*